Viridian Therapeutics, Inc. (LON:0K1R)
28.63
-1.62 (-5.36%)
Feb 12, 2026, 4:19 PM GMT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $70.57M USD in the quarter ending September 30, 2025, with 81,958.14% growth. This brings the company's revenue in the last twelve months to $789.00K, up 161.26% year-over-year. In the year 2024, Viridian Therapeutics had annual revenue of $302.00K, down -3.82%.
Revenue (ttm)
$789.00K
Revenue Growth
+161.26%
P/S Ratio
39.94
Revenue / Employee
$5.52K
Employees
143
Market Cap
2.10B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | 939.00K | 37.00% |
| Dec 31, 2015 | 2.54M | -1.78M | -41.25% |
| Dec 31, 2014 | 4.32M | 4.00K | 0.09% |
| Dec 31, 2013 | 4.32M | -90.04K | -2.04% |
| Dec 31, 2012 | 4.41M | 2.49M | 130.01% |
| Dec 31, 2011 | 1.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.80M |
| Oxford Nanopore Technologies | 204.69M |
| Oxford Biomedica | 151.21M |
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| 4basebio | 1.78M |
Viridian Therapeutics News
- 9 days ago - Viridian Therapeutics (VRDN) Receives Updated Analyst Rating from Wells Fargo | VRDN Stock News - GuruFocus
- 17 days ago - Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - Seeking Alpha
- 5 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price Target | VRDN Stock News - GuruFocus
- 5 weeks ago - Viridian Therapeutics Prepares for Transformational 2026 - Benzinga
- 5 weeks ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 5 weeks ago - Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
- 7 weeks ago - FDA Accepts Viridian's Veligrotug BLA For Priority Review In Thyroid Eye Disease - Nasdaq